GENE ONLINE|News &
Opinion
Blog

2021-12-06| In-depthInterviewsM&A

How CDMOs are Restructuring the Biopharma Landscape – An Interview with Bobby Sheng

by Tyler Chen
Share To
Bora Pharmaceuticals is a CDMO that has been on a roll. The company gained attention with its acquisition of GlaxoSmithKline’s (GSK) facility in Canada and Eisai’s production plant in Taiwan. In an interview with GeneOnline, CEO of Bora Pharmaceuticals, Bobby Sheng gives his take on how to cultivate a CDMO by taking into account three trends that define the industry as well as the prerequisites for a successful CDMO M&A. 

Log in now to read

LATEST
Biotech Showcase 2022: Healing the Psyche with Psychedelia
2022-01-17
Sex Dimorphism in Obesity and the Impact of Estrogen Hormone Therapy on Cardiometabolic Health
2022-01-17
ARM 2022: Industry Briefs on Cell and Gene Therapies
2022-01-17
Study Reveals a Form of Four-Stranded DNA that Links Protein Deficiency and Premature Aging
2022-01-17
Shanghai’s Everest Medicines Licenses Covid-19 Oral Antivirals from Singapore’s National Drug Discovery Platform
2022-01-17
Digital Health Programme to Connect British and Taiwanese Leaders
2022-01-17
Pfizer: Pneumonia Shot Can Be Given with COVID-19 Vaccine in Older Adults
2022-01-16
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!